These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31734230)

  • 21. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.
    Takenaka A; Yamada Y; Miyake H; Hara I; Fujisawa M
    Int J Urol; 2008 Apr; 15(4):309-13. PubMed ID: 18380817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer.
    Ericson KJ; Murthy PB; Bryk DJ; Ramkumar RR; Broughman JR; Khanna A; Mian OY; Campbell SC
    Clin Adv Hematol Oncol; 2019 Dec; 17(12):697-707. PubMed ID: 31851158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes.
    Moschini M; Shariat SF; Abufaraj M; Soria F; Klatte T; Croce G; Mattei A; Damiano R; Salonia A; Montorsi F; Briganti A; Colombo R; Gallina A
    Urol Oncol; 2017 Apr; 35(4):151.e17-151.e23. PubMed ID: 27932269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
    Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
    J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urothelial Carcinoma In Situ of the Bladder With Glandular Differentiation: Report of 92 Cases.
    Yang Z; Epstein JI
    Am J Surg Pathol; 2018 Jul; 42(7):971-976. PubMed ID: 29683821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
    Guo CC; Fine SW; Epstein JI
    Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy.
    Heide T; Maurer A; Eipel M; Knoll K; Geelvink M; Veeck J; Knuechel R; van Essen J; Stoehr R; Hartmann A; Altmueller J; Graham TA; Gaisa NT
    J Pathol; 2019 Jun; 248(2):230-242. PubMed ID: 30719704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Laparoscopic radical cystoprostatectomy: our experience in a consecutive series of 10 patients with a 3 years follow-up.
    Simonato A; Gregori A; Lissiani A; Bozzola A; Galli S; Gaboardi F
    Eur Urol; 2005 Jun; 47(6):785-90; discussion 790-2. PubMed ID: 15925074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ureteral carcinoma in situ at radical cystectomy: does the margin matter?
    Silver DA; Stroumbakis N; Russo P; Fair WR; Herr HW
    J Urol; 1997 Sep; 158(3 Pt 1):768-71. PubMed ID: 9258077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
    Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
    J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
    Tilki D; Reich O; Svatek RS; Karakiewicz PI; Kassouf W; Novara G; Ficarra V; Chade DC; Fritsche HM; Gerwens N; Izawa JI; Lerner SP; Schoenberg M; Stief CG; Skinner E; Lotan Y; Sagalowsky AI; Shariat SF
    J Urol; 2010 May; 183(5):1757-63. PubMed ID: 20299059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 expression in patients with advanced urothelial cancer of the urinary bladder.
    Shariat SF; Bolenz C; Karakiewicz PI; Fradet Y; Ashfaq R; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Rigaud J; Müller SC; Lerner SP; Montorsi F; Sagalowsky AI; Cote RJ; Lotan Y
    BJU Int; 2010 Feb; 105(4):489-95. PubMed ID: 19659466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interest of next-generation sequencing in BCG-treated high-risk bladder cancer.
    Jungels C; Martinez Chanza N; Albisinni S; Mercier M; d'Haene N; Rorive S; Roumeguère T
    Prog Urol; 2018 May; 28(6):344-350. PubMed ID: 29673906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and molecular markers of urothelial premalignancy and malignancy.
    Cordon-Cardo C; Cote RJ; Sauter G
    Scand J Urol Nephrol Suppl; 2000; (205):82-93. PubMed ID: 11144907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacillus Calmette-Guérin treatment of urothelial carcinoma arising in the ileal neobladder after radical cystectomy.
    Yamashita R; Matsuzaki M; Niwakawa M; Ito I
    Int J Urol; 2014 Mar; 21(3):333-4. PubMed ID: 23991753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
    Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
    PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of Ki67 and p63 expressions in bladder cancer patients who underwent radical cystectomy.
    Wang L; Zhou M; Feng C; Gao P; Ding G; Zhou Z; Jiang H; Wu Z; Ding Q
    Int Urol Nephrol; 2016 Apr; 48(4):495-501. PubMed ID: 26759323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.